Social stratification in the dissemination of statins after stroke in Sweden

European Journal of Clinical Pharmacology

Volumn 69, Issue 5, 2013, Pages 1173-1180

  Sjölander, Maria ^a   Eriksson, Marie ^b   Glader, Eva Lotta ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Brain infarction; Ethnic groups; Secondary prevention; Socioeconomic status; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; BIRTHPLACE; BRAIN ISCHEMIA; EDUCATIONAL STATUS; FEMALE; HOSPITAL DISCHARGE; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SOCIAL STATUS; SWEDEN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DRUG UTILIZATION; ETHNIC GROUPS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; REGISTRIES; SEX CHARACTERISTICS; SOCIOECONOMIC FACTORS; STROKE; SWEDEN;

EID: 84879461730     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1454-8     Document Type: Article

References (35)

1. [No authors listed](1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383-1389
2. [No authors listed] (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339(19):1349-1357
3. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. (1999) Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99(2):216-223 (Pubitemid 29056362)
4. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7-22 (Pubitemid 34756487)
5. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355(6):549-559 (Pubitemid 44202151)
6. O'Regan C, Wu P, Arora P, Perri D, Mills EJ (2008) Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 121(1):24-33
7. Manktelow BN, Potter JF (2009) Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev (3):CD002091
8. Socialstyrelsen (2006) Nationella riktlinjer för strokesjukvård 2005 (National guidelines for stroke care 2005) (in Swedish). The Swedish National Board of Health and Welfare, Stockholm. Available at: http://www.socialstyrelsen.se/
9. Hälso-och sjukvårdslag SFS 1982:736. [Health and Medical Service Act] Stockholm: Socialdepartementet (in Swedish)
10. Socialstyrelsen (2009) Folkhälsorapport 2009 [Public Health Report 2009] Socialstyrelsen: Stockholm (in Swedish)
11. Black D, Smith C, Whitehead M (1982) Inequalities in health: The Black report. Penguin, London
12. Marmot M, Wilkinson R (2006) Social determinants of health. Oxford University Press, Oxford
13. Marmot MG (2004) The Status Syndrome: how social standing affects our health and longevity. Times Books, New York
14. Li C, Hedblad B, Rosvall M, Buchwald F, Khan FA, Engström G (2008) Stroke incidence, recurrence, and case-fatality in relation to socioeconomic position. Stroke 39(8):2191-2196
15. Kuper H, Adami H-O, Theorell T, Weiderpass E (2007) The socioeconomic gradient in the incidence of stroke. Stroke 38(1):27-33 (Pubitemid 46035602)
16. Julian TH (1971) The inverse care law. Lancet 297(7696):405-412
17. Asplund K, Hulter Åsberg K, Appelros P, Bjarne D, Eriksson M, Johansson Å, et al. (2011) The Riks-Stroke story: building a sustainable national register for quality assessment of stroke care. Int J Stroke 6(2):99-108
18. Riks-Stroke. Available at: http://www.riks-stroke.org/index.php?content= start Accessed 22 April 2012
19. SCB. Longitudinal integration database for health insurance and labour market studies (LISA). Available at: http://www.scb.se/Pages/List-257743.aspx Accessed 14 May 2012
20. Geleedst-De Vooght M, Schalekamp T, Mantel-Teeuwisse A, Jansen P (2010) Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs Aging 27(7):589-596
21. Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G (2007) Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health 17(5):492-496 (Pubitemid 350033999)
22. Mungall MMB, Gaw A, Shepherd J (2003) Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 20(4):263-275 (Pubitemid 36403429)
23. Sanossian N, Ovbiagele B (2009) Prevention and management of stroke in very elderly patients. Lancet Neurol 8(11):1031-1041
24. Alhusban A, Fagan SC (2011) Secondary prevention of stroke in the elderly: a review of the evidence. Am J Geriatr Pharmacother 9(3):143-152
25. Glader E-L, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester P-O, et al. (2003) Sex differences in management and outcome after stroke: a Swedish National perspective. Stroke 34(8):1970-1975 (Pubitemid 36944792)
26. Eriksson M, Glader E-L, Norrving B, Terent A, Stegmayr B (2009) Sex differences in stroke care and outcome in the Swedish National Quality Register for Stroke Care. Stroke 40(3):909-914
27. Sjölander M, Eriksson M, Glader E-L (2012) Few sex differences in the use of drugs for secondary prevention after stroke: a nationwide observational study. Pharmacoepidemiol Drug Saf 21(9):911-919
28. Ringbäck Weitoft G, Ericsson Ö, Löfroth E, Rosén M (2008) Equal access to treatment? Population-based follow-up of drugs dispensed to patients after acute myocardial infarction in Sweden. Eur J Clin Pharmacol 64(4):417-424
29. Ohlsson H, Rosvall M, Hansen O, Chaix B, Merlo J (2010) Socioeconomic position and secondary preventive therapy after an AMI. Pharmacoepidemiol Drug Saf 19(4):358-366
30. Addo J, Ayerbe L, Mohan KM, Crichton S, Sheldenkar A, Chen R, Wolfe CDA, McKevitt C (2012) Socioeconomic status and stroke. Stroke 43(4):1186-1191
31. Cockburn J, Pit S (1997) Prescribing behaviour in clinical practice: patients' expectations and doctors' perceptions of patients' expectations - a questionnaire study. Br Med J 315(7107):520-523 (Pubitemid 27359105)
32. Jorgensen T, Johansson S, Kennerfalk A, Wallander M, Svardsudd K (2001) Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 35(9):1004-1009 (Pubitemid 32880015)
33. Henricson K, Stenberg P, Rametsteiner G, Ranstam J, Hanson BS, Melander A (1998) Socioeconomic factors, morbidity and drug utilization - an ecological study. Pharmacoepidemiol Drug Saf 7(4):261-267 (Pubitemid 28396297)
34. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG (2003) Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 89(4):417-421 (Pubitemid 36379415)
35. Margulis AV, Choudhry NK, Dormuth CR, Schneeweiss S (2011) Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. Pharmacoepidemiol Drug Saf 20(10):1088-1097